# OnCo record paper-therap-lancet-oncol-2024-update (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-therap-lancet-oncol-2024-update/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-therap-lancet-oncol-2024-update" ;
  schema:name "Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial"@en ;
  schema:description "Later report from the TheraP trial registered as NCT03392428, in The Lancet Oncology (2024); its title describes an updated or longer-term analysis."@en ;
  schema:url <https://onco.cc/key-papers/paper-therap-lancet-oncol-2024-update/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(23)00529-6>, <https://pubmed.ncbi.nlm.nih.gov/38043558/>, <https://europepmc.org/article/MED/38043558>, <https://clinicaltrials.gov/study/NCT03392428> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(23)00529-6> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Hofman MS, Emmett L, Sandhu S, et al." ;
  onco:trials <https://onco.cc/trials/therap/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .